We have previously characterised a PET imaging-based peptide biomarker targeting granzyme B ([18F]AlF-mNOTA-GZP) and demonstrated that it can successfully stratify tumours responding to combinations of immune therapeutics from non-responding tumours [17,18]. The gene discussed is GZMB; the disease is neoplasm.